Pfizer and BioNTech have delayed plans to seek emergency use authorization for a COVID-19 vaccine for children 6 months to 4 years old.
The companies on Friday announced plans to extend their rolling submission to the Food and Drug Administration due to the need for additional time to look at data from ongoing clinical trials.
